Victory Capital Management Inc. Sells 16,794 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Victory Capital Management Inc. decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 20.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,279 shares of the biotechnology company’s stock after selling 16,794 shares during the period. Victory Capital Management Inc. owned about 0.07% of Sarepta Therapeutics worth $8,278,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after purchasing an additional 317,277 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Sarepta Therapeutics by 2,257.8% during the first quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock valued at $31,135,000 after buying an additional 230,300 shares during the last quarter. Rhumbline Advisers raised its position in shares of Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after purchasing an additional 160,942 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after acquiring an additional 131,112 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Trading Down 0.3 %

Shares of SRPT stock opened at $110.50 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $10.55 billion, a PE ratio of 88.40 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25. The firm has a 50 day moving average price of $122.21 and a two-hundred day moving average price of $131.71.

Analysts Set New Price Targets

A number of research analysts have weighed in on SRPT shares. UBS Group lifted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Guggenheim upped their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Citigroup dropped their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.